295 related articles for article (PubMed ID: 33575206)
1. Comprehensive Characterization of Alternative mRNA Splicing Events in Glioblastoma: Implications for Prognosis, Molecular Subtypes, and Immune Microenvironment Remodeling.
Zhao L; Zhang J; Liu Z; Wang Y; Xuan S; Zhao P
Front Oncol; 2020; 10():555632. PubMed ID: 33575206
[TBL] [Abstract][Full Text] [Related]
2. Development of a Nomogram With Alternative Splicing Signatures for Predicting the Prognosis of Glioblastoma: A Study Based on Large-Scale Sequencing Data.
Wang Z; Gao L; Guo X; Feng C; Lian W; Deng K; Xing B
Front Oncol; 2020; 10():1257. PubMed ID: 32793502
[No Abstract] [Full Text] [Related]
3. Systemic characterization of alternative splicing related to prognosis, immune infiltration, and drug sensitivity analysis in ovarian cancer.
Liu Q; Zhang H; Yang X; Liu X; Yin F; Guo P; Yin Y; Zheng K; Yang Z; Han Y
Ann Transl Med; 2022 Jan; 10(2):126. PubMed ID: 35282039
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
5. The systematic identification of survival-related alternative splicing events and splicing factors in glioblastoma.
Peng T; Liu Z; Zhang Y; Liu X; Zhao L; Ma Y; Fan J; Song X; Wang L
Ann Hum Genet; 2024 Jul; 88(4):320-335. PubMed ID: 38369937
[TBL] [Abstract][Full Text] [Related]
6. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
8. Role of alternative splicing signatures in the prognosis of glioblastoma.
Xie ZC; Wu HY; Dang YW; Chen G
Cancer Med; 2019 Dec; 8(18):7623-7636. PubMed ID: 31674730
[TBL] [Abstract][Full Text] [Related]
9. Construction of a breast cancer prognosis model based on alternative splicing and immune infiltration.
Zhang D; Lu W; Zhuo Z; Mei H; Wu X; Cui Y
Discov Oncol; 2022 Aug; 13(1):78. PubMed ID: 35988113
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
Li Y; Guo D
BMC Cancer; 2021 Aug; 21(1):958. PubMed ID: 34445990
[TBL] [Abstract][Full Text] [Related]
11. Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Zhao L; Zhang J; Xuan S; Liu Z; Wang Y; Zhao P
Front Cell Dev Biol; 2021; 9():600506. PubMed ID: 33614641
[No Abstract] [Full Text] [Related]
12. A Prediction Model Using Alternative Splicing Events and the Immune Microenvironment Signature in Lung Adenocarcinoma.
Zhu L; Wang Z; Sun Y; Giamas G; Stebbing J; Yu Z; Peng L
Front Oncol; 2021; 11():778637. PubMed ID: 35004299
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome analysis and prognostic model construction based on splicing profiling in glioblastoma.
Qiu J; Wang C; Hu H; Chen S; Ding X; Cai Y
Oncol Lett; 2021 Feb; 21(2):138. PubMed ID: 33552257
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
15. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of Prognostic Alternative Splicing Signature Reveals Recurrence Predictor for Papillary Thyroid Cancer.
Liu M; Khushbu RA; Chen P; Hu HY; Tang N; Ou-Yang DJ; Wei B; Zhao YX; Huang P; Chang S
Front Oncol; 2021; 11():705929. PubMed ID: 34722250
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma.
Wang M; Zhou Z; Zheng J; Xiao W; Zhu J; Zhang C; Jiang X
Front Oncol; 2021; 11():650153. PubMed ID: 34055619
[TBL] [Abstract][Full Text] [Related]
18. Identification of Survival-Associated Alternative Splicing Signatures in Lung Squamous Cell Carcinoma.
Liu Y; Jia W; Li J; Zhu H; Yu J
Front Oncol; 2020; 10():587343. PubMed ID: 33117720
[No Abstract] [Full Text] [Related]
19. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
20. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
Cancer Cell Int; 2021 Apr; 21(1):190. PubMed ID: 33794886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
